
Clinical Trials - December 12, 2023
Mendus announces positive Phase 2 data
Mendus has reported positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel in acute myeloid leukemia (AML). The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from the current standard of care in AML maintenance therapy, the company states. “We are obviously very pleased […]